ERC Medical News Today reported that top-line results year lorcaserin Bloom - DM test demonstrated statistically significant weight And Fat loss in patients with type 2 diabetes. In this Test, lorcaserin three co-primary efficacy end met. In Also, as described below, lorcaserin patients taking lorcaserin 10 Mg twice daily achieved statistically significant improvements in Secondary end including HbA1c, as compared to patients random to placebo. Bloom - studied 604 obese and overweight patients with type and evaluate DM 2 diabetes. Patients were randomized to 10 mg bid lorcaserin. Three 52-week primary efficacy ends were as follows: Patients who lost 5 percentage of their baseline body ratio at least Weight, body weight change in the baseline, and proportion Patients of their baseline body weight lost at least 10 percentages. Using Modified intent to treat last observation carried forward Analysis, lorcaserin 10 mg bid received three primary efficacy end statistically significant weight loss compared to placebo by producing. 52 weeks, 37.5 percentages of patients treated with 10 mg lorcaserin Bid least 5 percentage weight loss of more than doubling the 16.1 percentage achieved at Patients taking placebo. Patients treated with lorcaserin 10 mg bid Gain 4.5 percentage 1.5 percentage mean weight loss than for to placebo. In addition, lorcaserin 16.3 percentage of 52 Week 10 mg bid patients Get the least weight loss, 4.4 percentages of patients taking 10 percentages less than placebo. Mg twice daily to achieve statistically significant improvement HbA1c including several secondary endpoints, compared with patients random to placebo. Bloom - 604 DM study and evaluation of patients with type Fat 2 diabetes. Patients were randomized to 10 mg bid lorcaserin. Three primary efficacy endpoints at 52 weeks were as follows: Patients less than 5 percentage of their baseline body loses Baseline body weight, weight changes, and the ratio Patients of their baseline body weight at least 10 percentages. Use Modified intent - to treat last observation carried forward Analysis, 10 mg bid Three primary efficacy endpoints lorcaserin statistically significant weight loss compared with placebo by producing. 52 weeks, 37.5 percentage of patients treated with 10 mg lorcaserin Bid at least 5 percentage weight loss, more than double to reach 16.1 percentage Patients received placebo. Patients treated with 10 mg bid lorcaserin 4.5 percentages with an average weight loss 1.5 percentage compared with the reach for to placebo. After 52 weeks, 10 lorcaserin 16.3 percentage of patients mg bid Scored at least 10 percentage weight loss compared with 4.4 percentage of patients, placebo.